HoneyLab founded by Laurence Greig and Professor Shaun Holt.
HoneyLab receives TechNZ funding from Foundation for Research Science and Technology for clinical trial for topical viral condition.
HoneyLab receives TechNZ funding from Foundation for Research Science and Technology for research into topical treatment of acne using kanuka honey.
HoneyLab receives close to $1 million in private equity investment to support continued clinical trials work and product development of their unique kanuka honey products and bee venom treatments.
Frances Stead (Ex Managing Director L’Oreal NZ and marketing director Proctor and Gamble) appointed to HoneyLab Board.
HoneyLab receives project funding support from Callaghan Innovation for protection of unique formulations using pharmaceutical grade kanuka honey.
HoneyLab lodges 3 novel patents in the USA for their unique formulations.
HoneyLab lodges patent in the USA for its unique bee venom collection system. The system is solar powered, and causes no harm to the bees.
HoneyLab receives support from Callaghan innovation to conduct phase 3 clinical trials for Rosacea.
HoneyLab enters partnership agreement with Department of Conservation.
Mayo Clinic (Minnesota, USA) enters research collaboration with Honeylab through their Complementary Medicines research group.
Full-time CEO appointed.
HoneyLab wins Wellington Gold Awards for Discovering Gold for our Honevo® product development.
HoneyLab completes phase 3 clinical trial of Honevo® for rosacea and shows it is an effective treatment for the condition
Phase 3 trial of Honevo for rosacea published in the British Medical Journal Open.
HoneyLab wins ‘Most Innovating Business’ in the David Awards.
HoneyLab signs first Chinese distribution agreement.
Company launches the worlds second largest ever phase 3 trial for cold sores covering 950 patients.